Table 4.
Clinical trials employing CAR-T cells or CAR-NK cells in AML.
| CAR Target | Effector Cell | Phase | Patients/Cells/ Indications |
Country | NCT |
|---|---|---|---|---|---|
| Lewis Y | T | I | Myeloma, AML, MDS | Australia | NCT01716364 |
| CD33 | T | I | CD33+ AML | USA | NCT03126864 |
| CD33 | T | I | R/R AML | China | NCT02799680 |
| CD33 | T | I/II | R/R AML | China | NCT01864902 |
| CD33 | NK | I/II | R/R CD33+ AML | China | NCT02944162 |
| CD123 | T | I | CD123+ AML | China | NCT03585517 |
| CD123 | T | I | relapsed AML after HSCT | China | NCT03114670 |
| CD123 | T | I/II | R/R AML | China | NCT03556982 |
| CD123 | T | I | R/R AML | USA | NCT02623582 |
| CD123 | T | I | R/R AML and R/R blastic plasmacytoid DCN | USA | NCT02159495 |
| CD123 | T | I | R/R AML | China | NCT03672851 |
| CD123 | T | I | R/R AML | USA | NCT03766126 |
| UCART 123 | T | I | R/R AML and newly diagnosed high-risk AML | USA | NCT03190278 |
| CD123/CLL-1 | T | II/III | R/R AML | China | NCT03631576 |
| CD33, CD38, CD56, CD117, CD123, CD34, Muc1 | T | I | R/R AML, MDS, ALL | China | NCT03291444 |
| CD33, CD38, CD56, CD117, CD123, CD133, CD34 or Muc1 | T, TT | I | R/R AML | China | NCT03473457 |
| CD33, CD38, CD56, CD123, CLL-1, Muc1 | T | I/II | AML | China | NCT03222674 |
| NKG2D | T | I | AML, MDS-RAEB, Multiple Myeloma | USA | NCT02203825 |
| NKG2D (NKR2) | T | I/II | R/R AML, Myeloma | USA + Belgium |
NCT03018405 |
Abbreviations: CAR, chimeric antigen receptor; NCT, national clinical trial identifier; NK, natural killer cell; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; R/R, refractory/resistant; USA, United States of America; HSCT, hematopoietic stem cell transplantation; DCN, dendritic cell neoplasm; T, CAR-T cells; TT, double CAR-T cells; NK, CAR-natural killer cells; RAEB, refractory anemia with excess of blasts; NKG2D, natural killer group 2D antigen.